Business Context and Reporting Period
This Form 8-K was filed by Fulcrum Therapeutics, Inc. on March 23, 2021. The report discloses the appointment of Judith A. Dunn, Ph.D., as President, Research and Development, effective April 1, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Base Salary: $450,000 annually.
- Target Bonus: 40% of annual base salary (discretionary).
- Equity Grant: Option to purchase 215,000 shares of common stock.
- Option Exercise Price: Closing price of common stock on the effective date (April 1, 2021).
- Vesting Schedule: 25% on the first anniversary; remaining 75% in equal quarterly installments over the subsequent 12 quarters.
Material Changes
The primary material change is the addition of Dr. Dunn to the executive leadership team. No financial performance changes or balance sheet adjustments are reported in this document.
Outlook, Risks, and Contingencies
Compensatory Arrangements and Termination:
- Termination without Cause/Good Reason (Outside Change in Control): Entitlement to accrued salary/benefits, 12 months of continued base salary, and up to 12 months of health coverage premium payments.
- Termination without Cause/Good Reason (Within 12 Months of Change in Control): Entitlement to accrued obligations, 12 months of base salary, up to 12 months of health coverage, 100% of target bonus, and full acceleration of time-based equity vesting.
- Indemnification: The Company may be required to indemnify Dr. Dunn for expenses, judgments, fines, and settlements arising from her service as an officer.
Investor Verification Checklist
- Verify the closing stock price on April 1, 2021, to determine the exercise price of the 215,000 share option grant.
- Review the Company's 10-Q for the quarter ending March 31, 2021, for the full text of the Employment Agreement.
- Assess the impact of the new executive's compensation package on the Company's cash burn rate and future dilution.
- Confirm Dr. Dunn's prior board service at Seelos Therapeutics, Inc., as disclosed in the filing.